Galderma rolls out Alastin across JPAC region, extending its regenerative skincare portfolio beyond injectables and fillers.
Galderma has launched Alastin regenerative skincare across Japan and key Asia Pacific markets, expanding its footprint beyond its core neuromodulator and filler business. Alastin's product line—peptide-based serums and treatments designed to support skin recovery post-procedure—targets the lucrative adjunctive-care segment that practices increasingly bundle with injectables and laser treatments.
This move reflects Galderma's strategy to capture higher lifetime patient value through skincare recommendations and retail margins. The Asia Pacific region, with rising aesthetic-procedure volume and growing middle-class demand, represents a high-growth market for both professional-grade and consumer skincare.
Galderma extends Alastin regenerative skincare across Asia Pacific to capture post-procedure skincare margins.
For practices, Alastin's expansion signals Galderma's intent to compete with Allergan's SkinMedica and Revance's Enerpeel in the post-procedure recovery space. Practices already using Galderma injectables (Dysport, Restylane) may see bundled pricing or co-marketing support to drive skincare adoption.
Source: original report ↗
Frequently asked questions
What is Alastin skincare and what does it do?
Alastin is a line of peptide-based serums and treatments designed to support skin recovery after aesthetic procedures like injectables and laser treatments. It's positioned as an adjunctive-care product that practices bundle with their core treatments to enhance results and improve patient outcomes.
Why are medspa practices adding post-procedure skincare lines like Alastin?
Post-procedure skincare drives higher lifetime patient value and retail margins beyond injectable and filler revenue. By bundling products like Alastin with injectables and laser treatments, practices can increase average transaction value and improve patient satisfaction during recovery.
How does Galderma's Alastin compete with SkinMedica and Enerpeel?
Alastin competes in the post-procedure recovery skincare segment alongside Allergan's SkinMedica and Revance's Enerpeel. Galderma's advantage is its existing relationship with practices already using Dysport and Restylane, allowing bundled pricing and co-marketing support to drive adoption.
Why is Galderma expanding Alastin into Asia Pacific markets?
Asia Pacific has rising aesthetic-procedure volume and growing middle-class demand for both professional-grade and consumer skincare. The region represents a high-growth market where Galderma can extend its regenerative skincare portfolio beyond its core neuromodulator and filler business.
What pricing or incentives might practices get for bundling Alastin with Galderma injectables?
Practices using Galderma injectables like Dysport and Restylane may receive bundled pricing discounts or co-marketing support to encourage Alastin adoption. These incentives are designed to make it easier for established Galderma customers to add skincare to their service offerings.
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.
